Saba Speaks to Tipifarnib and Targeting HRAS in Head and Neck Cancer
Season 4, Episode 5, Nov 12, 2020, 08:10 PM
In our exclusive interview, Nabil F. Saba, MD, FACP, sheds light on the implications of targeting HRAS in head and neck squamous cell carcinoma, details the data that has been reported to date with tipifarnib, and shares his expectations for the ongoing KO-TIP-007 trial.